A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.

Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.

The observation could pave the way for a blood test to predict disease progression in people with a genetic predisposition to developing the neurodegenerative disorder.

Federal prosecutors filed criminal charges that allege the company’s promise to revolutionize blood testing swindled investors out of hundreds of millions of dollars and put patients in danger.

The company raised more than $700 million based on false claims to investors, according to the complaint.

The diagnostic measures two proteins indicative of brain injury.

The test uses levels of plasma amyloid-β to estimate the buildup of protein plaques in the brain.

A newly identified marker for a common pancreatic cancer may help doctors detect the disease in its earlier stages.

The blood-testing startup settles a legal dispute with the Arizona attorney general’s office.